Cargando…
Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
Due to their alleged analgesic, anti-inflammatory and tissue regenerative effects, capacitive-resistive electrothermal therapy (CRET), which is based on non-invasive exposure to radiofrequency (RF) currents, is often applied to chemotherapeutically treated patients with cancer. Our previous studies...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488331/ https://www.ncbi.nlm.nih.gov/pubmed/34630714 http://dx.doi.org/10.3892/ol.2021.13068 |
_version_ | 1784578142039441408 |
---|---|
author | Hernández-Bule, María Luisa Martínez, María Antonia Trillo, María Ángeles Martínez, Lidia Toledano-Macías, Elena Úbeda, Alejandro |
author_facet | Hernández-Bule, María Luisa Martínez, María Antonia Trillo, María Ángeles Martínez, Lidia Toledano-Macías, Elena Úbeda, Alejandro |
author_sort | Hernández-Bule, María Luisa |
collection | PubMed |
description | Due to their alleged analgesic, anti-inflammatory and tissue regenerative effects, capacitive-resistive electrothermal therapy (CRET), which is based on non-invasive exposure to radiofrequency (RF) currents, is often applied to chemotherapeutically treated patients with cancer. Our previous studies have demonstrated that subthermal CRET currents can elicit a number of cell responses, including anti-proliferative effects, in the human liver cancer cell line HepG2. Such effects involve significant changes in the regulation of proteins involved in MAPK signaling pathways, which are also implicated in the cancer cell response to standard anticancer drugs such as sorafenib. This overlap in response pathways may lead to competitive, neutralizing or blocking interactions between the electrical and chemical treatments, thus raising questions on the advisability of CRET treatment for their analgesic, anti-inflammatory or other purposes in patients undergoing chemotherapy. The present study analyzed the effects of simultaneous treatment with sorafenib and 448-kHz, subthermal CRET current on the proliferation and viability of HepG2 cell cultures. Cell viability was assessed through Trypan blue or XTT assays, while flow cytometry was applied for cell cycle and apoptosis analysis. The expression of proteins involved in cell proliferation were assessed by immunoblotting and immunofluorescence. The results revealed no evidence to suggest that the electrical treatment counteracted or neutralized the cellular response to sorafenib at the different conditions evaluated. Furthermore, at the standard pharmacological sorafenib concentration, 5 µM, the combined treatment elicited an anti-proliferative response significantly stronger than that induced by each of the treatments when applied separately in HepG2 cells. These data do not support the hypothesis that CRET exposure may inhibit or diminish the effects of a chemotherapeutic drug used in cancer treatment, and highlights the requirement for further investigation into the cell response to the combined action of electrical and chemical treatments. |
format | Online Article Text |
id | pubmed-8488331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-84883312021-10-07 Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current Hernández-Bule, María Luisa Martínez, María Antonia Trillo, María Ángeles Martínez, Lidia Toledano-Macías, Elena Úbeda, Alejandro Oncol Lett Articles Due to their alleged analgesic, anti-inflammatory and tissue regenerative effects, capacitive-resistive electrothermal therapy (CRET), which is based on non-invasive exposure to radiofrequency (RF) currents, is often applied to chemotherapeutically treated patients with cancer. Our previous studies have demonstrated that subthermal CRET currents can elicit a number of cell responses, including anti-proliferative effects, in the human liver cancer cell line HepG2. Such effects involve significant changes in the regulation of proteins involved in MAPK signaling pathways, which are also implicated in the cancer cell response to standard anticancer drugs such as sorafenib. This overlap in response pathways may lead to competitive, neutralizing or blocking interactions between the electrical and chemical treatments, thus raising questions on the advisability of CRET treatment for their analgesic, anti-inflammatory or other purposes in patients undergoing chemotherapy. The present study analyzed the effects of simultaneous treatment with sorafenib and 448-kHz, subthermal CRET current on the proliferation and viability of HepG2 cell cultures. Cell viability was assessed through Trypan blue or XTT assays, while flow cytometry was applied for cell cycle and apoptosis analysis. The expression of proteins involved in cell proliferation were assessed by immunoblotting and immunofluorescence. The results revealed no evidence to suggest that the electrical treatment counteracted or neutralized the cellular response to sorafenib at the different conditions evaluated. Furthermore, at the standard pharmacological sorafenib concentration, 5 µM, the combined treatment elicited an anti-proliferative response significantly stronger than that induced by each of the treatments when applied separately in HepG2 cells. These data do not support the hypothesis that CRET exposure may inhibit or diminish the effects of a chemotherapeutic drug used in cancer treatment, and highlights the requirement for further investigation into the cell response to the combined action of electrical and chemical treatments. D.A. Spandidos 2021-11 2021-09-23 /pmc/articles/PMC8488331/ /pubmed/34630714 http://dx.doi.org/10.3892/ol.2021.13068 Text en Copyright: © Hernández-Bule et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Hernández-Bule, María Luisa Martínez, María Antonia Trillo, María Ángeles Martínez, Lidia Toledano-Macías, Elena Úbeda, Alejandro Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
title | Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
title_full | Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
title_fullStr | Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
title_full_unstemmed | Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
title_short | Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
title_sort | response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488331/ https://www.ncbi.nlm.nih.gov/pubmed/34630714 http://dx.doi.org/10.3892/ol.2021.13068 |
work_keys_str_mv | AT hernandezbulemarialuisa responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent AT martinezmariaantonia responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent AT trillomariaangeles responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent AT martinezlidia responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent AT toledanomaciaselena responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent AT ubedaalejandro responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent |